Eleven Biotherapeutics: BioCentury Newsmakers in the Biotech Industry Conference (Eleven Biotherapeutics) - Sep 11, 2015 - Anticipated initiation of second P3 trial for allergic conjunctivitis in mid-2016; Anticipated BLA filing for allergic conjunctivitis in H2 2017
Anticipated BLA • Anticipated new P3 trial • Immunology
|